19 February 2019
MycoTechnology, a FoodTech company, has raised $30 million in a Series C funding round
The latest investment will help drive expansion and accelerate research & development to introduce new and novel ingredients to the market.
Life Sciences
30 January 2019
MycoTechnology Raises $30 Million in Series C Financing Round with Investments from the Biggest Names in Food
The $30 million in new investment will fuel expansion and accelerate R&D project execution. This funding round opens up an opportunity to explore different ways to meet...
18 January 2019
Cees de Jong: new Chairman of the joint start-up A-Mansia Biotech
A-Mansia Biotech, a microbiome company, has announced the appointment of Cees de Jong as the Chairman of its Board of Directors. His experience of successfully managing several...
13 December 2018
Israeli microbiome co BiomX teams with Johnson & Johnson
Israeli microbiome company BiomX, which is developing customized phage therapies, has announced that it has entered into a collaboration with Janssen the therapy R&D arm of...
5 November 2018
Next decade set to herald industry confidence in microbiome-based therapies, says new report
Taking on board learnings from challenges already faced and focusing on advanced, longer-term studies of variables within microbiome research will be key to fostering...
25 October 2018
Microbiotica Attracts Equity Investment from Seventure’s Health for Life Capital™ Fund
The company, which was founded in 2016 to develop transformational technology developed at the Sanger Institute, has made rapid progress in developing a unique capability to...
23 October 2018
Enterome signs global licensing, co-development and co-promotion agreement with Takeda for the treatment of Crohn’s disease
Enterome, a clinical-stage biotech company developing innovative therapies to treat microbiome-associated diseases with a focus on auto-immune disease and cancer, has entered...
16 October 2018
LNC Therapeutics acquires exclusive license for the Christensenella patent from Cornell University
LNC aims to develop the first Christensenella-based drug candidate for the treatment of obesity and metabolic disorders
4 October 2018
Vedanta Biosciences Announces Successful Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303
Vedanta Biosciences, a clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human...
1 October 2018
LNC Therapeutics launches a new clinical trial, OBEMINALE 2, and treats its first patient
LNC Therapeutics, a French biotech company specialized in the gut microbiome-based drug discovery,has announced the launch of a new clinical trial with Stablor®, OBEMINALE 2,...